%0 Journal Article
%T Body mass index influences the response to infliximab in ankylosing spondylitis
%A S¨¦bastien Ottaviani
%A Yannick Allanore
%A Florence Tubach
%A Marine Forien
%A Ana£¿s Gardette
%A Blandine Pasquet
%A Elisabeth Palazzo
%A Marine Meunier
%A Gilles Hayem
%A Chantal Job-Deslandre
%A Andr¨¦ Kahan
%A Olivier Meyer
%A Philippe Dieud¨¦
%J Arthritis Research & Therapy
%D 2012
%I BioMed Central
%R 10.1186/ar3841
%X In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously). After 6 months of treatment, changes from baseline in BASDAI, Visual Analogue Scale (VAS) pain, C-reactive protein (CRP) level, and total dose of nonsteroidal antiinflammatory drug (NSAID) were dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary variables assessing response to IFX (BASDAI50, VAS50, CRP50, NSAID50). Whether the BMI was predictive of the response to IFX therapy according to these definitions was assessed with logistic regression.Multivariate analysis found that a higher BMI was associated with a lower response for BASDAI50 (P = 0.0003; OR, 0.87; 95% CI (0.81 to 0.94)), VAS50 (P < 0.0001; OR, 0.87; 95% CI (0.80 to 0.93)); CRP50 (P = 0.0279; OR, 0.93; 95% CI (0.88 to 0.99)), and NSAID50 (P = 0.0077; OR, 0.91; 95% CI (0.85 to 0.97)), criteria. According to the three WHO BMI categories, similar results were found for BASDAI50 (77.6%, 48.9%, and 26.5%; P < 0.0001), VAS50 (72.6%, 40.4%, and 16.7%; P < 0.0001); CRP50 (87.5%, 65.7%, and 38.5%; P = 0.0001), and NSAID50 (63.2%, 51.5%, and 34.6%; P = 0.06).This study provides the first evidence that a high BMI negatively influences the response to IFX in AS. Further prospective studies, including assessment of the fat mass, pharmacokinetics, and adipokines dosages are mandatory to elucidate the role of obesity in AS IFX response.Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health [1]. A crude population measure of obesity is the body mass index (BMI). Individuals with a BMI of 30 kg/m2 or more are considered obese.It is now well known that pharmacokinetic variables of drug clearance and volume of distribution (Vd) could be influenced by overweight and obesity [2]. In addition, adipose tissue can exert both endocrine and immune effects on multiple other organs thr
%U http://arthritis-research.com/content/14/3/R115